ArticleFrontiers in public health2025
Molecular and seroepidemiology of SARS-CoV-2 among influenza-like illness and severe Acute respiratory illness cases in selected health facilities in Ethiopia.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic Characterization and Evolutionary Dynamics of SARS-CoV-2 Lineage NB.1.8.1 in Thailand, 2025.Viruses · 2026Article
- Integrated surveillance in Kilifi reveals continued SARS-CoV-2 circulation and immune escape of emerging JN.1 sublineages post-pandemic.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SARS-CoV-2 remains globally circulating, yet post-pandemic comprehensive molecular, serological, and population-level immunity data from low-resource settings such as Ethiopia are limited. This study employed genomic surveillance with seroepidemiological assessment to characterize the epidemiology of SARS-CoV-2 among individuals presenting with influenza-like illness (ILI) and severe acute respiratory infection (SARI) between May 2023 and April 2024 across 21 influenza sentinel surveillance sites representing diverse regions of Ethiopia. Methods: Respiratory swabs from 8,881 ILI/SARI patients were tested for SARS-CoV-2 by real-time polymerase chain reaction (RT-PCR). Whole-genome sequencing was performed on samples with cycle threshold (Ct) values ≤ 30 using Oxford Nanopore Technology, and serological testing was performed on blood samples collected from participants aged ≥12 years using the WANTAI enzyme-linked immunosorbent assay (ELISA) targeting the spike receptor-binding domain (RBD). Results: Among 8,881 participants, the overall SARS-CoV-2 detection rate was 3.3 (95% CI: 2.9-3.6). Compared to children under 2 years, older age groups had significantly higher odds of infection: 15-49 years (AOR: 1.60; 95% CI: 1.16-2.21), 50-64 years (AOR: 2.15; 95% CI: 1.31-3.54), and ≥65 years (AOR: 2.37; 95% CI: 1.42-3.95). ILI cases demonstrated higher positivity than SARI cases (AOR: 2.26; 95% CI: 1.75-2.91). SARS-CoV-2 was detected across all seasons, with positivity rates ranging from 1.9% in spring to 6.0% in summer. Whole-genome sequencing of ( Conclusions: This study demonstrates the continued circulation of SARS-CoV-2 in Ethiopia, primarily among adults with influenza-like illness, with distinct seasonal peaks during the summer. The Omicron variant remained dominant, with JN.1 and its descendants prevailing since late 2023 in parallel with a national rise in COVID-19 cases. These findings reinforce that ongoing genomic and syndromic surveillance utilizing established ILI/SARI platforms remain vital for monitoring viral evolution and guiding targeted public health interventions in low-resource settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.